Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Perseus ProteomicsTSE:4882 +2.56%56 PB Ratio is 2.23 as of Jul. 16, 2026, which is 25% below its 10-year median of 2.96. GuruFocus rates TSE:4882 with a GF Score™ of 56/100 and a GF Value™ of 円439.72 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 922 Drug Manufacturers companies, Perseus Proteomics ranks worse than 55.42% on this metric.
Perseus Proteomics Inc stock PB Ratio (=2.21) is close to 2-year low of 2.04.
The historical rank and industry rank for Perseus Proteomics's PB Ratio or its related term are showing as below:
TSE:4882'
s PB Ratio Range Over the Past 10 Years
Min: 1.12 Med: 2.96 Max: 8.83
Current: 2.24
During the past 9 years, Perseus Proteomics's highest PB Ratio was 8.83. The lowest was 1.12. And the median was 2.96.
TSE:4882's PB Ratio is ranked worse than 55.42% of 922
companies
in the Drug Manufacturers industry
Industry Median: 1.955
vs TSE:4882: 2.24
During the past 12 months, Perseus Proteomics's average Book Value Per Share Growth Rate was -26.20% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -29.40% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -16.10% per year.
During the past 9 years, the highest 3-Year average Book Value Per Share Growth Rate of Perseus Proteomics was 56.40% per year. The lowest was -29.40% per year. And the median was -5.30% per year.
Back to Basics: PB Ratio
Perseus Proteomics (TSE:4882) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Perseus Proteomics PB Ratio Related Terms
Perseus Proteomics PB Ratio Historical Data
* Premium members only.
The historical data trend for Perseus Proteomics's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Perseus Proteomics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Perseus Proteomics PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Perseus Proteomics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Perseus Proteomics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Perseus Proteomics (TSE:4882) has a PB Ratio of 2.23 as of Jul. 16, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Perseus Proteomics and its competitors. This is 25% below median its historical median of 2.96. Over the past decade, Perseus Proteomics' PB Ratio has ranged from 1.12 to 8.83. According to the industry distribution chart, Perseus Proteomics ranks #511 out of 922 companies in the Drug Manufacturers industry, placing it in the top 55.4%.
Is Perseus Proteomics' PB Ratio too high?
Perseus Proteomics' current PB Ratio of 2.23 is 25% below median its 10-year median of 2.96. Over the past 10 years, this metric has ranged from a low of 1.12 to a high of 8.83. The Drug Manufacturers industry median PB Ratio is 1.96. Perseus Proteomics' value of 2.23 is 14.1% above this industry median. Based on the distribution chart, Perseus Proteomics ranks #511 out of 922 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Perseus Proteomics has a GF Score™ of 56/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Perseus Proteomics' PB Ratio compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Perseus Proteomics ranks #511 out of 922 companies for PB Ratio. This places Perseus Proteomics in the lower half of its industry. The industry median PB Ratio is 1.96. Perseus Proteomics' value of 2.23 is 14.1% above this benchmark. Historically, Perseus Proteomics' own PB Ratio has ranged from 1.12 to 8.83 over the past decade. While the company's 10-year median is 2.96 vs. the industry median of 1.96, Perseus Proteomics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.96, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Perseus Proteomics's current PB Ratio of 2.23 is 14.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Perseus Proteomics and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Perseus Proteomics's current PB Ratio is 2.23, which is 25% below median its own 10-year median of 2.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Perseus Proteomics stock overvalued right now?
Based on GuruFocus' analysis, Perseus Proteomics (TSE:4882) is currently considered Significantly Undervalued. The stock's GF Value™ is 円439.72, compared to a current price of 円160.00 — trading 63.6% below its estimated fair value. The current PB Ratio is 2.23, which is 25% below median its 10-year median of 2.96 and 14.1% above the Drug Manufacturers industry median of 1.96. Perseus Proteomics' overall GF Score™ is 56/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Perseus Proteomics (TSE:4882), the current PB Ratio is 2.23 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Perseus Proteomics (TSE:4882) Overvalued in 2026?
Based on GuruFocus' analysis, Perseus Proteomics stock appears to be undervalued.
The current stock price of 円160.00 is trading 63.6% below its estimated GF Value™ of 円439.72.
GuruFocus considers Perseus Proteomics to be Significantly Undervalued.
Key valuation signals for TSE:4882:
PB Ratio: 2.23 (25% below median its 10-year median of 2.96)
GF Value™: 円439.72 vs. price of 円160.00 (63.6% below fair value)
Industry Position: 14.1% above the Drug Manufacturers median (#511 of 922)
No single metric tells the full story. See the TSE:4882 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Perseus Proteomics Inc is engaged in the research and development, manufacture, and sales of pharmaceuticals. It provides antibody-based therapeutics and diagnostic drugs to cure cancer and other diseases. The Company operates in a single segment, the pharmaceutical business.
56GF Score
Get the complete analysis for TSE:4882
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4882 has been successfully added to your 
